Abstract
Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Current Pharmaceutical Biotechnology
Title: MicroRNAs in Tumorigenesis
Volume: 8 Issue: 6
Author(s): Kai Ove Skaftnesmo, Lars Prestegarden, David R. Micklem and James B. Lorens
Affiliation:
- Department of Biomedicine,University of Bergen, N-5009 Bergen Norway.,Norway
Keywords: RNA, microRNA, cancer
Abstract: Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Export Options
About this article
Cite this article as:
Skaftnesmo Ove Kai, Prestegarden Lars, Micklem R. David and Lorens B. James, MicroRNAs in Tumorigenesis, Current Pharmaceutical Biotechnology 2007; 8(6) . https://dx.doi.org/10.2174/138920107783018390
DOI https://dx.doi.org/10.2174/138920107783018390 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neonatal Germ Cell Tumors
Current Pediatric Reviews Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Collagen: The Oldest Scaffold for Tissue Regeneration
Current Tissue Engineering (Discontinued) Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks
Current Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Analgesic Effects and Assays of Controlled-Release Tramadol and O-Desmethyltramadol in Cancer Patients with Pain
Current Pharmaceutical Biotechnology From Ocean to Bedside: the Therapeutic Potential of Molluscan Hemocyanins
Current Medicinal Chemistry Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design The Role of Proteomics in Osteoarthritis Pathogenesis Research
Current Drug Targets Subject Index to Volume 3
Current Gene Therapy Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Microbial Lifestyle and Genome Signatures
Current Genomics Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry